<DOC>
	<DOCNO>NCT00005941</DOCNO>
	<brief_summary>RATIONALE : Giving low dos chemotherapy , fludarabine , radiation therapy donor peripheral blood stem cell transplant help stop growth cancer cell . It also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune system help destroy remain cancer cell ( graft-versus-tumor effect ) . Giving infusion donor 's T cell ( donor lymphocyte infusion ) transplant may help increase effect . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving cyclosporine mycophenolate mofetil transplant may stop happen . PURPOSE : This phase II trial study well donor peripheral stem cell transplant plus chemotherapy total-body irradiation follow donor white blood cell infusion work treat patient recurrent metastatic locally advanced cancer cervix vagina associate human papillomavirus .</brief_summary>
	<brief_title>Peripheral Stem Cell Transplant , White Blood Cell Infusions , Chemotherapy , Radiation Therapy Treating Patients With Recurrent Metastatic Cervical Vaginal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine partial complete response patient recurrent metastatic locally advanced human papillomavirus ( HPV ) -associated cervical vaginal carcinoma treat nonmyeloablative regimen comprise fludarabine low-dose total body irradiation follow allogeneic peripheral blood stem cell transplantation , cyclosporine , mycophenolate mofetil , donor lymphocyte infusion . Secondary - Determine toxicity regimen patient . - Determine whether regimen induces engraftment donor chimerism patient . - Determine HPV-E6 HPV-E7 specific T-cell response select patient treated regimen . OUTLINE : This pilot study . Patients receive condition therapy comprise fludarabine IV day -4 -2 low-dose total body irradiation day 0 . Filgrastim ( G-CSF ) -mobilized allogeneic peripheral blood stem cell infuse day 0 . Patients also receive oral cyclosporine twice daily day -3 35 tapered day 56 . Mycophenolate mofetil administer orally twice daily day 0-27 . Patients disease progression graft-versus-host disease day 56 receive nonmobilized donor lymphocyte infusion ( DLI ) 30 minute day 65 . DLI may repeat every 65 day 4 dos . Patients follow weekly 3 month , monthly 6 month , every 6 month 2 year , annually 5 year . PROJECTED ACCRUAL : A total 10 patient accrue study .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Vaginal Neoplasms</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm recurrent metastatic locally advanced cervical vaginal carcinoma curable surgery radiotherapy Tumor human papillomavirus positive polymerase chain reaction Bidimensionally measurable disease clinical examination radiographic image Availability genotypically HLAidentical sibling donor ( exclude identical twin ) No brain metastases PATIENT CHARACTERISTICS : Age : Under 65 Performance status : Karnofsky 80100 % Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) SGOT SGPT great 2 time ULN Renal : Creatinine clearance least 40 mL/min Cardiovascular : Cardiac ejection fraction least 40 % No history congestive heart failure No poorly control hypertension Pulmonary : No severe defect pulmonary function No supplementary continuous oxygen Other : Not pregnant nursing Fertile patient must use effective contraception 12 month study completion HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : Concurrent growth factor severe persistent febrile neutropenia transplantation allow Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics Surgery : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>stage III cervical cancer</keyword>
	<keyword>recurrent cervical cancer</keyword>
	<keyword>stage IVB cervical cancer</keyword>
	<keyword>stage IVA cervical cancer</keyword>
	<keyword>stage III vaginal cancer</keyword>
	<keyword>stage IVA vaginal cancer</keyword>
	<keyword>stage IVB vaginal cancer</keyword>
	<keyword>recurrent vaginal cancer</keyword>
</DOC>